venetoclax + mitoxantrone liposome

venetoclax + mitoxantrone liposome is a combination therapy regimen being investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML). The regimen combines venetoclax, an orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), with mitoxantrone liposome (PLM60), a nanoparticle-based formulation of the cytotoxic anthracenedione mitoxantrone. Venetoclax works by selectively binding to and inhibiting the anti-apoptotic protein BCL-2, which is frequently overexpressed in AML cells, thereby restoring the natural apoptotic process. Mitoxantrone liposome acts as a DNA intercalator and topoisomerase II inhibitor, with its liposomal encapsulation modifying its pharmacokinetics and tissue distribution to potentially enhance efficacy and reduce toxicity compared to conventional mitoxantrone. This combination is currently being evaluated in Phase I/II clinical trials led by investigator Hui Zeng at the First Affiliated Hospital of Jinan University to determine the maximum tolerated dose and clinical efficacy in patients with difficult-to-treat AML.

Brand names

VenclextaDuoenyiVenclyxto

Other names

Mito-LMitoxantrone hydrochloride liposomeMitoxantrone liposome